Gene Expression of \(ABCG1\), \(ABCG2\), and \(ABCB1\) and Their Role in Iranian Pediatric Patients with Acute Lymphoblastic Leukemia’s Recurrence

Narjes Mehrvar \(1,2,*\), Mohammad Reza Rezvany \(2,3,\), Hassan Abolghasemi \(4\), Mohammad Esmaeil Akbari \(5\), Javad Sabery Nejad \(5\), Azim Mehrvar \(5,6\), Mohammad Faranoush \(7,6\), Maryam Gheidi Shahnaz \(2\) and Abolfazl Movafagh \(8,1, **\)

1Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran  
2Hematology Department, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran  
3Department of Oncology-Pathology, Immune and Gene Therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna and Karolinska Institutet, Stockholm, Sweden  
4Pediatric Congenital Hematologic Disorders Research Center, Research Institute for Childen’s Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran  
5AJA University of Medical Sciences, Tehran, Iran  
6MAHAK Hematology Oncology Research Center (MAHAK-HORC), MAHAK Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran  
7Pediatric Growth and Development Research Center, Institute of Endocrinology and Metabolism, Iran University of Medical Sciences, Tehran, Iran  
8Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran  

*Corresponding author: Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Email: narjes.mehrvar@gmail.com  
**Corresponding author: Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Email: movafagh_a@yahoo.com

Received 2019 May 10; Revised 2019 September 04; Accepted 2019 September 04.

Abstract

**Background:** Expression of ATP-binding cassette (ABC) transporters could be correlated with drug resistance and treatment failures like recurrence in pediatric patients with acute lymphoblastic leukemia (ALL). The relation of ABC gene expression and relapse in ALL is still unclear. This might be important especially in regions with a high rate of relapse.

**Objectives:** This study aimed to evaluate the role of \(ABCG1\), \(ABCG2\), and \(ABCB1\) gene expression in the recurrence of Iranian pediatric patients with ALL.

**Methods:** Iranian pediatric patients with confirmed ALL were enrolled in this study as two groups; relapsed ALL and a control group consisting of 3 years relapse-free survival (RFS). Real Time-PCR was done with \(GAPDH\) for expressing \(ABCG1\), \(ABCG2\), and \(ABCB1\) transporter genes. Cumulative doses of VCR (vincristine), DNR (daunorubicin), and L-ASP (L-asparaginase) were calculated for each patient. The gathered data were analyzed with SPSS version 22 and REST 2009 software.

**Results:** Total of 39 samples (23 cases; 16 controls) were enrolled during 26 months. High expression of \(ABCG1\) (P value = 0.0068), \(ABCG2\) (P value = 0.0120) and low expression of \(ABCB1\) (P value = 0.0029) related with conferring increased risk of relapse in the patients. The mean relative folds of expressions were 2.3, 1.8, and 1.07 for \(ABCG1\), \(ABCG2\), and \(ABCB1\), respectively. In addition achieved expression pattern was related to high doses of VCR, DNR, and L-ASP.

**Conclusions:** Designed expression pattern have the predictive value for estimating of conferring relapse in Iranian pediatric patients with diagnosed ALL.

**Keywords:** ABC Transporters, Gene Expression, Pattern, Relapse

1. Background

The rate of treatment in pediatric patients with acute lymphoblastic leukemia (ALL) depends on the region where they are treated (1). Recently 5-year overall survival rate improved to more than 90% worldwide (2). Literature reviews on Iranian pediatric patients with ALL reveal variant survival rates (3-6). In this regard, improving the outcome and prognosis of pediatric patients with ALL are the most important challenges for a physician. Treatment failures will impact on the overall survival of patients. Resistance to chemotherapy drugs is the main cause of treatment failures (7), and thus recurrence is the prominent challenge of those failures (8). Nearly 10% - 15% of pediatric patients with ALL will confer with relapse (9).

Different cellular mechanisms can lead to multidrug resistance (MDR), but one of the most important issues is the expression of ATP-Binding cassette transporters (10-12). \(ABCB1\) gene (located on chromosome 7q21) is known as multidrug resistance gene 1 (MDR1). Encoding P-glycoprotein (P-gp) can cause resistance to chemotherapy agents such as adriamycin (Adr), daunorubicin (DNR), paclitaxel, vin-
cristine (VCR), and vinblastine (13-16). ABCG2 gene (located on chromosome 4q22.1) which encodes breast cancer resistance protein (BCRP) has an important role in resistance to mitoxantrone, methotrexate (MTX), cladribine, and topotecan (1). ABCG1 gene (located on chromosome 21q22.3) also known as ABCB1 or WHITE1 (17) can make resistance to doxorubicin (18). Still published reports about multidrug resistance by ABCG1 in pediatric malignancies are rare.

2. Objectives

This study was designed because of two challengeable issues: (1) prominent rate of relapse in Iranian pediatric patients with ALL; (2) rare studies about the affection of ABCG1, ABCG2 and ABCB1 genes’ expression on chemotherapy regimens of mentioned patients. The main objective of this study was whether the gene expression of ABCG1, ABCG2, and ABCB1 has a role in the recurrence of Iranian pediatric patients with ALL.

3. Methods

3.1. Patients

Enrolled children consisted of patients younger than 15 years old with the immune-phenotyping report of ALL who referred to an NGO referral childhood’s malignancy center (MAHAK Pediatric Cancer Treatment and Research Center) in Tehran, Iran. The study conducted case-control designing for evaluating gene expression of ABCG1, ABCG2, and ABCB1. Inclusion criteria for two groups were as: (1) the case group consisted of mentioned patients who had relapse immediately or during their chemotherapy and at the time of the study were still administrating with chemotherapy regimens; the control group implied aforementioned patients who completed the treatment without any recurrence and at the time of study had 3 years relapse-free survival (RFS).

3.2. The Cumulative Dose of Chemotherapy Agents

The chemotherapy regimen of patients was based on the ALL-BFM (Berlin-Frankfurt-Munster) protocol 2009. Cumulative doses of administered chemotherapy agents in the induction phase were calculated. Cumulative dose of administered chemotherapy agents in the ALL-BFM (Berlin-Frankfurt-Munster) protocol 2009. Cumulative doses of administered chemotherapy agents in the ALL-BFM (Berlin-Frankfurt-Munster) protocol 2009. Cumulative doses of administered chemotherapy agents in the ALL-BFM (Berlin-Frankfurt-Munster) protocol 2009. Cumulative doses of administered chemotherapy agents in the ALL-BFM (Berlin-Frankfurt-Munster) protocol 2009. Cumulative doses of administered chemotherapy agents in the ALL-BFM (Berlin-Frankfurt-Munster) protocol 2009. Cumulative doses of administered chemotherapy agents in the ALL-BFM (Berlin-Frankfurt-Munster) protocol 2009.

3.3. Total RNA Isolation

Three milliliter of peripheral blood (PB) obtained from each child in the stylenediaminetetraacetic acid (EDTA) blood sample tubes. Subsequently, the peripheral blood was immediately transferred to the laboratory. White blood cells were separated from PBs by Red Blood Cell Lysis Buffer (RBCL) and were suspended in Phosphate-buffered saline (PBS) (22). Total RNA was isolated by Ytisol pure RNA reagent according to the instruction manual (cat No.: YT9063, Yekta Tajhiz Azma, Tehran, Iran). The concentration of total RNA was considered by Thermo Scientific NanoDrop (Thermo Fisher Scientific, USA) and the purity was checked by OD260/OD280 absorption. Total RNAs had been stored in -70°C until cDNA synthetizing.

3.4. cDNA Synthesis

cDNA was prepared using the standard of total RNA. cDNA synthesis kit (Yekta Tajhiz) was used. The template RNA (based on 1 µg) was mixed with 1 µL random hexamer primer and finalized with DEPC (diethyl pyrocarbonate)-treated water to the volume of 13.4 µL. After incubation at 70°C for 5 minutes, each product was mixed with 4 µL of 5 × first strand buffer, 1 µL dNTP, 0.5 µL RNasin, and 1 µL of MMLV. The mixture was incubated for 1 hour at 37°C and terminated by heating at 70°C for 5 minutes. Finally, PCR products of synthesizing were stored in -70°C for real-time PCR section.

3.5. Real-Time PCR (RT-PCR)

Primers for ABCG1, ABCG2, and ABCB1 genes (23) were designed according to the Table 1. GAPDH gene was used for the normalization of the results through RT-PCR with a forward primer (5' - 3'): GAAGGTGGAAGTGCGGATC and reverse primer (5' - 3'): GAAGATGGTGATGGGATTTC (24, 25). The specificity of primers had been checked with primer blast (26). All primers were obtained from Pishgam Biotech (Tehran, Iran). Primers had been purified with MOPCTM purification method.

Before starting RT-PCR, products of cDNA synthesizes had been diluted as 1:3. For making a mixture of RT-PCR, 0.5 µL of forwarding primer + 0.5 µL of reverse primer + cDNA template according to 1 µg/µL + 7.5 µL of Syber Green QPCR master mix 2 × added together and with nuclease-free water, the final reaction volume became 20 µL. The RT-PCR

2. Int J Cancer Manag. 2019; 12(11):e93300.
program had been set up as: one cycle of pre-incubation (95°C = 300 s); 38 cycles of 3 steps amplification (95°C = 60 s, 60°C = 60 s, 72°C = 30 s), and one cycle of melting (95°C = 10 s, 65°C = 60 s, 97°C = 1 s). Quantifications had been done by LightCycler 96 real-time PCR Cycler (Hoffmann-La Roche AG, Basel, Switzerland). For checking the fluorescent signals of specific bands, all of the RT-PCR products were run by 1.5% agarose gel electrophoresis.

3.6. Statistical Analysis

Raw data were analyzed by light cycler software. Relative expression analysis was done by REST 2009 software. Statistical calculations were performed using SPSS version 22 software. Student’s t-test and chi-square were used for consideration differences between groups. P value was defined as ≤ 0.05 for significant relations. Pfaffl test was used for evaluating the relative expression of genes in two groups of case and control.

3.7. Informed Consent

Informed consent was obtained for peripheral blood sampling from enrolled patients. In this regard, all of the experiments were performed in compliance with the relevant laws. The Ethical Committee of Shahid Beheshti University of Medical Sciences approved this study.

4. Results

4.1. Patients

A total of 39 children with ALL were enrolled in this study. During 16 months, there were 23 patients for the case and 16 patients for the control groups.

The male to female ratio in this study was 1.3 (male = 22; female = 17). The mean age at diagnosis was 6.1 ± 4.1 years old (range 7 months to 14 years old). Immune-phenotypes of patients were as: Pre-B = 21; early Pre-B = 13; T-cell = 3; Pro-B = 2. Bone marrow aspiration (BMA) at the end of induction showed that 63% had complete remission, 29.6% as hypo-cellular and 7.4% as partial remission.

Sites of relapse in the patients in the case group were as: CNS = 55%; bone marrow = 25%; testis = 13%, and one patient had relapsed at bone marrow and CNS. The median time of relapse from diagnosis for those mentioned patients was 23 months (range 65 days to 5 years).

Table 2 shows patients’ characterizations according to the case and control groups.

4.2. Patients’ Follow-Up

At the time of preparing this manuscript, 9 patients from the case group died because of their relapse. The median follow-up time for all of the patients was 4 years (range 14 months to 10 years). The median follow-up time for patients in the case and control group was 36 and 61 months, respectively. The 3-year overall survival and 5-year overall survival according to Kaplan-Meier analysis were: 82.3% ± 0.06 and 75.4% ± 0.07, respectively.

4.3. Cumulative Doses

The maximum and mean (± SD) cumulative dose of VCR were 90.9 mg/m² and 38.5 ± 22 mg/m², respectively (low dose: 34.5%, intermediate dose: 20.7%, and high dose: 44.8%). The maximum and mean (± SD) cumulative dose of DNR were 185 mg/m² and 67.3 ± 43.5 mg/m², respectively (standard dose: 81.8%, high dose: 18.2%). Based on the results the maximum and mean (± SD) cumulative dose of L-ASP were 92500 u/m² and 43894.26 ± 22777.9 u/m², respectively (standard dose: 78.6% and high dose: 21.4%). Table 2 shows cumulative doses of chemotherapy agents of the induction phase based on two considered groups.

4.4. Expression of ABCG1, ABCG2, and ABCB1 by RT-PCR

The reaction efficiency for GAPDH was 98%, while it was 96% for ABCG1, ABCG2, and ABCB1 genes (27). The relative expression analysis of ABC transporters’ genes is summarized in Table 3.

Patients with relapse had the significantly more relative expression of ABCG1 (P value = 0.0068), ABCG2 (P value = 0.0120) and less expression of ABCB1 (P value = 0.0029) in comparison to patients who had 3-year RFS. The relative fold of expressions in the case of the group according to Pfaffl test was summarized in Table 3, Figure 1 shows the relative expression of ABC transporters’ genes in the patients using REST 2009 software.

Analyses of paired t-test samples for considering the relation between means of ABC transporters’ gene expression and administrative cumulative dose of chemotherapy agents revealed significant relation (P values = 0.0001). High doses of VCR, DNR, and L-ASP led to high expression of ABCG1 and ABCG2.

5. Discussion

Multidrug resistance as a major issue through induction chemotherapy in pediatric patients with acute leukemia is still a prominent topic in cancer research (28, 29). Modifying in gene expression of ABC transporters can lead to MDR (30). In the present study, gene expression of ABCG1, ABCG2, and ABCB1 were evaluated in pediatric patients with ALL. The resulted data approved that there was...
Table 2. Patients’ Characteristics and Cumulative Doses of Chemotherapy Agents According to Case and Control Groups

| Male/Female | Mean age at DX ± SD, y | Immune Phenotypes, N | BMA, % | VCR, % | DNR, % | LASP, % |
|-------------|-------------------------|----------------------|--------|--------|--------|---------|
| Case (n = 23) | 17/6 (2.8) | 5.1 ± 0.9 | 3 | 0 | 2 | 2 | 50 | 35.7 | 14.3 | 28.6 | 75 | 25 | 84.6 | 15.4 |
| Control (n = 16) | 5/11 (0.4) | 7.3 ± 1.0 | 8 | 7 | 1 | - | 76.9 | 23.1 | - | 15.5 | 24.7 | 80 | 90 | 10 | 73.3 | 26.7 |

Abbreviations: BMA, bone marrow aspiration; CR, complete remission; DNR, daunorubicin; DX, diagnosis; HC, hypo cellular; HD, high dose; ID, intermediate dose; LASP, L-asparginase; LD, low dose; PR, partial remission; SD, standard dose; VCR, vincristine.

Figure 1. The relative expression of considered genes in patient

Table 3. The Relative Expression of ABC Transporters’ Genes in Patients with Relapse in Comparison to Control Group

| Gene | Relative Expression | 95% Confidence Interval | P Value |
|------|---------------------|-------------------------|---------|
| ABCG1 | 2.373 | 0.157 - 36.607 | 0.0068 |
| ABCG2 | 1.834 | 0.140 - 22.248 | 0.0120 |
| ABCB1 | 1.07 | 0.069 - 19.605 | 0.0029 |

In 2017, Carrillo et al. devised a study on newly diagnosed patients with ALL to evaluate the expression of ABCB1 and ABCG2. Their results demonstrated high expression of mentioned genes in patients with ALL in comparison to healthy donors. Also, they suggested that early detection of ABCB1 could account as a risk factor diagnosis and following up of patients with ALL (1).

Rahgozar et al. (30) evaluated the expression of ABCB1 and ABCG2 in pediatric patients with ALL through two groups of new cases and relapsed ALL. Their results showed high expression of ABCG2 (1.35 ± 0.30) and low expression of ABCB1 in relapsed patients with ALL. According to those findings, they concluded that the expression of ABCG2 could be involved in the drug resistance of pediatric patients with ALL (30).

In another approach by Farawela et al. (31) gene expression of ABCB1 was evaluated in 37 Egyptian patients with ALL. Patients have consisted of new cases and individuals with complete remission, relapsed and resistant patients. Their findings revealed that there was a weak relation of gene expression of the aforementioned gene between new cases and relapsed ALL patients. Although ABCB1 had more expression in resistant patients (31).

There was a report that ABCG2 expresses nearly 13% - 40% in de novo cases with acute leukemia and 80% of patients with relapsed acute leukemia (31). In concordance with our findings, low expression of ABCB1 was also determined in some studies like in pediatric relapsed ALL patients by Lu et al. (32), or in young patients with relapsed ALL by Gurbuxani et al. (33), and finally the latest study by Farawela et al. who reported the low expression of ABCB1 in patients with relapsed ALL (31).

ABCG2 gene encodes breast cancer resistant protein (BCRP) which plays a role in resistance to mitoxantrone, doxorubicin, and daunorubicin (34). Overexpression of this gene has been reported through variant studies. Jaramillo et al. published a paper (2019) about the relation of some ABC transporters’ gene expression and MTX resistant in children with ALL. They highlighted that considered patients with overexpression of ABCG2 were resistant to MTX. Their results approved the chemoresistance feature of ABCG2’s overexpression (29).

Ross et al. (35) and Benderra et al. (36) approved high expression of ABCG2 which related to prognosis and sur-
vival rates of patients with AML in their studies. Sauerbrey et al. (37) carried out another study with controversial results on patients with ALL. Their results revealed that there were not any differences in the gene expression of ABCG2 in two groups of relapsed and new cases patients with ALL (37).

Results of this study do not have concordance with Sauerbrey’s report. In this study expression of ABCG2 in relapsed ALL cases was high. Also, this high expression was related to high doses of administered VCR, L-ASP, and DNR.

Published studies about the role of ABCGI in drug resistance are limited. In this regard, any information about multidrug resistance of this gene will be valuable. It is believed that the main role of ABCGI is homeostasis of cholesterol in macrophages (38). Denisov et al. (39) considered the drug-resistant profile by some ABC transporter genes in patients with different morphological breast cancer. It was found that ABCGI was expressed in all of the morphological forms of patients. They could only detect the expression in the level of protein by immunohistochemistry (39). Because of scarce data about this gene, there is not enough information if it expresses in hematologic malignancies or not.

In the present study, according to our information, it might be for the first time that gene expression of ABCGI was evaluated in pediatric patients with ALL. The analysis showed a significant correlation with the overexpression of ABCGI and recurrence of ALL. Due to this result, planning further studies about the multidrug resistance role of ABCGI is an inevitable value.

5.1. Conclusions

The main idea of devising this study was to determine whether the expression of ABCGI, ABCG2, and ABCB1 gene could be identified as the prominent risk factor of relapse in pediatric patients with ALL. The achieved data demonstrated that the expression of ABCGI and ABCG2 could be related to this hypothesis. Therefore the authors consisted of designing further cohort studies to evaluate the possible roles of these genes in prognosis and outcomes of pediatric patients with ALL. Impact of high drug expression notably ABCGI and ABCG2 could be account as prominent factors for conferring relapse in pediatric patients with ALL.

Acknowledgments

Authors have their great gratitude to the staffs of MAHAK Pediatric Cancer Treatment and Research Center.

Footnotes

Authors’ Contribution: All of the authors contribute in writing the manuscript.

Conflict of Interests: Authors declare that there is no conflict of interest.

Ethical Approval: This project was accepted in the Ethical Committee of Shahid Beheshti University of Medical Sciences with the ethical code of IR.SBMU.RETECH.REC.1396.533.

Funding/Support: This study does not have any financial support.

Informed Consent: Informed consent was obtained for peripheral blood sampling from enrolled patients. In this regard, all of the experiments were performed in compliance with the relevant laws.

References

1. Olarte Carrillo I, Ramos Penafiel C, Miranda Peralta E, Rozen Fuller E, Kassack Ipina JJ, Centeno Cruz F, et al. Clinical significance of the ABCB1 and ABCG2 gene expression levels in acute lymphoblastic leukemia. Hematology. 2017;22(5):286-91. doi: 10.1080/10245332.2016.1265780. [PubMed: 27960630].

2. Pui CH, Evans WE. A 50-year journey to cure childhood acute lymphoblastic leukemia. Semin Hematol. 2013;50(3):185-96. doi: 10.1053/j.seminhematol.2013.06.007. [PubMed: 23953314]. [PubMed Central: PMC3774944].

3. Parvareh M, Kahanani N, Farihmandinia Z, Nouri B. The survival rate of childhood leukemia and its related factors in Kerman, Iran. Iran J Health Sci. 2015;3(4):24-32.

4. Almasi-Hashiani A, Zareifar S, Karimi M, Khedmati E, Mohammadbelgi A. Survival rate of childhood leukemia in Shiraz, Southern Iran. Iran J Pediatr. 2013;23(1):53-6. [PubMed: 23550991]. [PubMed Central: PMC3574992].

5. Ayremilou P, Razavi SM, Solaymani-Dodaran M, Vakili M, Asadi-Lari M. Demographic and prognostic factors of 455 patients with acute childhood leukemia admitted to two referral hospitals in Tehran-Iran during ten years (2001-2011). Iran J Cancer Prev. 2012;5(3):157-63. [PubMed Central: 25628835]. [PubMed Central: PMC4294538].

6. Mehrvar A, Faranouz M, Hedayatinejad AA, Tashvighi M, Fazeli MA, Mehrvar N, et al. Epidemiological features of childhood acute leukemia at MAHAK’s Pediatric Cancer Treatment and Research Center (MPCTRC), Tehran, Iran. Basic Clin Cancer Res. 2015;7(1):9-15.

7. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011;29(5):532-41. doi: 10.1200/JCO.2010.30.1382. [PubMed: 21220592].

8. Gaynon PS. Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol. 2005;131(5):559-77. doi: 10.1111/j.1365-2141.2005.05773.x. [PubMed: 16351633].

9. Bhojwani D, Pui CH. Relapsed childhood lymphoblastic leukaemia. Lancet Oncol. 2013;14(6):e205-17. doi: 10.1016/S1470-2045(12)70580-6. [PubMed: 23639121].

10. Swerts K, De Moorloose B, Dhooe C, Laureys G, Benoit Y, Philippe J. Prognostic significance of multidrug resistance-related proteins in childhood acute lymphoblastic leukaemia. Eur J Cancer. 2006;42(5):395-409. doi: 10.1016/j.ejca.2005.09.017. [PubMed: 16324833].

11. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almqist KC, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 1992;258(5088):1650-4. doi: 10.1126/science.1380704. [PubMed: 1380704].

12. Leonard GD, Fejo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist. 2003;8(5):411-24. doi: 10.1634/theoncologist.8-5-411. [PubMed: 14504949].
Ambudkar SV, Sauna ZE, Gottesman MM, Szakacs G. A novel way to spread drug resistance in tumor cells: Functional intercellular transfer of P-glycoprotein (ABCB). Trends Pharmacol Sci. 2005;26(6):385-7. doi:10.1016/j.tips.2005.06.001. [PubMed: 15978880]. [PubMed Central: PMC1350964].

Marchetti S, Mazzanti R, Beijnen JH, Schellens JH. Concise review: Clinical relevance of drug drug and herb drug interactionsmediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist. 2007;12(8):927-41. doi:10.1614/theoncologist.12-8-927. [PubMed: 17766552].

Abd El-Ghaflar HA, Aladle DA, Farahat SE, Abd El-Hady N. P-glycoprotein (P-70) expression in acute leukemias. Hematology. 2006;11(3):35-41. doi:10.1080/10245330600262904. [PubMed: 16522547].

Suvannasankha A, Minderman H, O'Loughlin KL, Nakanishi T, Ford LA, Greco WR, et al. Breast cancer resistance protein (BCRP/MDR/ABCG2) in adult acute lymphoblastic leukemia: Frequent expression and possible correlation with shorter disease-free survival. Br J Haematol. 2004;127(4):392-8. doi:10.1111/j.1365-2141.2004.05211.x. [PubMed: 15520955].

NCBI. ABCG2 ATP binding cassette subfamily G member 1 [Homo sapiens (human)]. 2018, [cited 2018 Dec 23]. Available from: https://www.ncbi.nlm.nih.gov/gene/?term=9619

Gerashchenko TS, Denisov EV, Novikov NM, Tashireva LA, Kaigorodova EV, Savelieva OE, et al. Different morphological structures of breast tumors demonstrate individual drug resistance gene expression profiles. Exp Oncol. 2018;40(3):228-34. [PubMed: 30285501].

Hartman A, van den Bos C, Stijnen T, Pieters R. Decrease in motor performance in children with cancer is independent of the cumulative dose of vincristine. Cancer. 2006;106(6):395-401. doi:10.1002/cncr.2706. [PubMed: 16435332].

de Velde ME, Kaspers GL, Gnant F, Willem A, Ket JCF, van den Berg MH. Vincristine-induced peripheral neuropathy in children with cancer: A systematic review. Crit Rev Oncol Hematol. 2017;124:1-30. doi:10.1016/j.critrevonc.2017.04.007. [PubMed: 28477739].

Rammeloo LAJ, Postma A, Sobota-Plojhar MA, Bink-Boelkens ME, et al. Expression of genes related to multidrug resistance and apoptosis in acute leukemias: Frequent expression of ABCB1 in patients with acute leukemia. Br J Haematol. 2004;127(4):497-509. doi:10.1111/j.1365-2141.2004.05211.x. [PubMed: 15520955].

Rahgosar S, Moafi A, Abedi M, Entezar-e-ghaem M, Mostaghian J, Ghaedi K, et al. mRNA expression profile of multidrug-resistant genes in acute lymphoblastic leukemia of children, a prognostic value of ABCA3 and ABCA2. Cancer Biol Ther. 2014;15(3):35-41. doi:10.4161/cbr.26605. [PubMed: 24145440]. [PubMed Central: PMC4393522].

Farawala HM, Khorsheed MM, Kassem NM, Kassem HA, Zawam HM. The clinical relevance and prognostic significance of adenosine triphosphate ATP-binding cassette (ABCB) and multidrug resistance (MDR) genes expression in acute leukemia: An Egyptian study. J Cancer Res Clin Oncol. 2014;140(8):1332-30. doi:10.1007/s00432-014-1694-3. [PubMed: 24804845].

Yin R, Yang K, Sun L, Xiao Y, Pang X. Detection and clinical significance of multidrug resistance4 mRNA in bone marrow cells in children with acute lymphoblastic leukemia by real-time fluorescence quantitative RT-PCR. J Nanjing Med Univ. 2008;22(12):353-8. doi:10.4161/4706(08)60055-6.

Gurbuxani S, Sazawal S, Arya LS, Raina V, Marie JP, Bhargava M. MDR1 mRNA expression in young patients with acute lymphoblastic leukemia. Br J Haematol. 2000;109(4):487-9. doi:10.1046/j.1365-2141.2000.02475.x. [PubMed: 10970355].

Chen L, Manautou JE, Rasmussen TP, Zhong XB. Development of precision medicine approaches based on inter-individual variation of BCRP/ABCG2. Acta Pharm Sin B. 2009;9(4):659-74. doi:10.1016/j.apsb.2009.01.007. [PubMed: 19384528]. [PubMed Central: PMC664402].

Ross DD, Karp JF, Chen TT, Doyle LA. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood. 2006;108(1):365-8. doi:10.1182/blood-2005-12-4947. [PubMed: 18884767].

Benderra Z, Faussat AM, Sayada L, Perrot JY, Tang R, Chaoui D, et al. Expression of genes related to multidrug resistance and apoptosis in acutelymphoblasticleukemia. Br J Haematol. 2002;118(2):47-50. doi:10.1046/j.1365-2141.2002.03550.x. [PubMed: 12004041].

Schrijver A, Grawin R, Voigt A, Zintl F. Expression of the BCRP gene (ABCG2) in pediatric acute lymphoblastic leukemia. J Oncol Pharm Pract. 2010;16(3):179-88. doi:10.1177/1078029109351291. [PubMed: 19966624].

Denisov EV, Gerashchenko TS, Zavalova MV, Litvakov NV, Tsyganov MM, Kaigorodova EV, et al. Invasive and drug resistant expression profile of different morphological structures of breast tumors. Neoplasma. 2015;62(4):405-11. doi:10.4149/neop_2015_041. [PubMed: 25672673].